-
Protection Secretary Austin is ‘actively concerned and engaged’ whereas hospitalized
US Secretary of Defense Lloyd J. Austin testifies before a House Armed Services Committee hearing on the conclusion of military operations in Afghanistan at the Rayburn House Office building on Capitol Hill on September 29, 2021 in Washington, DC. Olivier Douliery | Afp | Getty Images Defense Secretary Lloyd Austin is still hospitalized following doctors’…
-
YouTube launches First Support Info Cabinets to assist in emergencies
People walk past a billboard advertisement for YouTube in Berlin, Germany, on Sept. 27, 2019. Sean Gallup | Getty Images YouTube is taking steps to fight against medical misinformation, especially when it comes to finding immediate tips on how to handle an emergency. The company on Wednesday introduced a feature called First Aid Information Shelves,…
-
Eli Lilly weight reduction drug web site might not upend business
Sopa Images | Lightrocket | Getty Images Eli Lilly is shaking up the pharmaceutical industry with a new website offering telehealth prescriptions and direct home delivery of certain drugs, including its red-hot weight loss treatment Zepbound, to expand patient access. The company’s direct-to-consumer push announced Thursday, the first of its kind for a big drugmaker,…
-
Medicare drug value negotiations what’s forward in 2024
Activists protest the price of prescription drug costs in front of the U.S. Department of Health and Human Services (HHS) building on October 06, 2022 in Washington, DC. Anna Moneymaker | Getty Images U.S. patients and drugmakers will get a first glimpse of how much Medicare can negotiate down drug prices in 2024, setting the…
-
Weight problems and Alzheimer’s medicine pack one-two punch to carry Eli Lilly
Investor optimism for Eli Lilly ‘s diabetes and obesity treatments in 2023 lifted the stock to its seventh annual gain in a row. In the new year, it should be the same old story. Shares of Eli Lilly have taken a breather over the past three months, as investors book profits in the top performer…
-
Bristol Myers Squibb to purchase Karuna Therapeutics
Bristol Myers Squibb on Friday announced it agreed to buy biopharmaceutical company Karuna Therapeutics for $14 billion in cash, or $330 per share. Karuna’s stock closed up more than 47% on the news Friday, hitting $317.85 a share. Bristol Myers Squibb shares closed up 2%. The deal will help expand Bristol Myers’ drug pipeline after…
-
New information on Eli Lilly’s weight-loss drug exhibits its outlook is vivid
The launch of Eli Lilly ‘s weight-loss drug Zepbound — a key pillar of our investment thesis in the pharmaceuticals giant — is going swimmingly in the U.S., Jefferies said Friday. Weekly Zepbound prescriptions totaled 7,700 in the week ended Dec. 8, its fourth on the U.S. market, according to Jefferies, which cited data compiled…
-
Moderna, Merck most cancers vaccine reduces danger of pores and skin most cancers return
An exterior view of Moderna’s clinical manufacturing facility. David L. Ryan | Boston Globe | Getty Images Moderna and Merck‘s experimental cancer vaccine, when used in combination with Merck’s blockbuster therapy Keytruda, reduced the risk of death or relapse in patients with the most deadly form of skin cancer after three years, according to midstage…
-
First CRISPR gene-editing remedy authorized in U.S.
The U.S. Food and Drug Administration on Friday approved the country’s first gene-editing treatment, Casgevy, for use in patients with sickle cell disease. The approval comes about a decade after the discovery of CRISPR technology for editing human DNA, representing a significant scientific advancement. Yet reaching the tens of thousands of people who could benefit…
-
Free ChatGPT might incorrectly reply drug questions, research says
Harun Ozalp | Anadolu | Getty Images The free version of ChatGPT may provide inaccurate or incomplete responses — or no answer at all — to questions related to medications, which could potentially endanger patients who use OpenAI’s viral chatbot, a new study released Tuesday suggests. Pharmacists at Long Island University who posed 39 questions…
